Dawnrays Pharma was founded in December 1995, it is principally engaged in the development, manufacture and sales of cephalosporin antibiotics and system specific medicines. Dawnrays Pharmaceutical (Holdings) Limited listed on the main board of The Hong Kong Stock Exchange on July 11, 2003 with stock code 02348.HK.

Dawnrays Pharma owns eight subsidiaries, namely Dawnrays International Company Limited, Dawnrays International Co., Ltd., Dawnrays Biotechnology Capital (Asia) Ltd., Suzhou Dawnrays Pharmaceutical Co., Ltd., Dawnrays Pharma (Hong Kong) Limited, Fujian Dawnrays Pharmaceutical Co., Ltd., Lanzhou Dawnrays Pharmaceutical Co., Ltd. and Suzhou Dawnrays Pharmaceuticals Trading Co., Ltd. As a Hong Kong listed company, Dawnrays Pharma strictly adheres to the requirements of Hong Kong's corporate governance in its overall decision-making and management. With global perspective and inclusiveness of the worldwide cultures, our business is on the track of internationalization, making Dawnrays Pharma a trustworthy enterprise for investors.

Dawnrays Pharma's cephalosporin antibiotics include intermediates, bulk medicines and powder for injections. The system specific medicines cover therapeutic areas for cardiovascular system, anti-HBV, anti-allergic, digestive system, urinary system, endocrine system with dosage forms of tablets, capsules and granules. For the production of cephalosporin antibiotics, Dawnrays Pharma adopts a distinctive comprehensive vertically integrated process from pharmaceutical intermediates to bulk medicines and FDFs, particularly in the area of chemical synthesis for the 3rd generation cephalosporin, with being equipped with high-end technology platforms, the quality of products has reached international advanced level, which has established an industrial chain of cephalosporin with extensive product portfolio, perfect comprehensive coordinated function, potentially high production capacity, hence Dawnrays Pharma is the first chosen raw material supplier for both major domestic and overseas pharmaceutical manufacturers.

Dawnrays Pharma's R & D center was founded in 2002 and upgraded to Suzhou Dawnrays Advanced Technology Research Institute in 2022. The Institute integrates internal and external resources with an "innovation incubator" type platform management and is dedicated to the R&D of innovative drugs with high clinical value, established a R&D system focusing on generic drugs, premium formulations and innovative drugs to provide strong technical support for Dawnrays Pharma. The Group's system specific medicines, Amlodipine besylate tablets"Amlozen^TM", Losartan potassium hydrochlorothiazide tablets"An Neixi", Cetirizine hydrochloride tablets"Cecoride^TM", Entecavir dispersible tablets"Rallyado^TM" are all the first batch of generics in China that received approval for launching generic drugs in China and their market shares have been ranked high.

Driven by the philosophy of "Attend to Health, Persist in Creation", Dawnrays Pharma is continuously improving and has been awarded honors of "National Torch Program Key High-tech Enterprise", "Top Ten Outstanding Enterprises of Jiangsu Province ", "Contract-abiding and Credit-worthy Enterprise in Jiangsu Province" , "Jiangsu Province Specialized, Fine, Unique and Innovative SMEs" and "Jiangsu Province Provincial Enterprise Technology Center". While pursuing development, Dawnrays Pharma has not forgotten to fulfill its corporate social responsibility. Since its establishment, Dawnrays Pharma has been actively involved in environmental protection, community charity, and took the initiative to assume social responsibility when the country suffered major natural disasters. Demanding itself as a model of corporate citizenship, Dawnrays Pharma established Dawnrays Love Fund in 2017, set up Dawnrays Volunteer Service Team and Hope School Scholarship Program, and joined Suzhou Wuzhong District Precision Assistance Alliance and Suzhou Volunteer Website. Relying on the government's public welfare platform, Dawnrays Pharma gives full play to the power of Dawnrays Love Fund in the community, and , has won a series of honors, such as "Model of Corporate Social Responsibility Construction ", in Jiangsu Province Advanced unit of Jiangsu Pharmaceutical Industry in "Fighting Against COVID-19" and "Enterprise with Outstanding Contribution to Tax Payment ".

Dawnrays Pharma will always be committed to the health of human beings as its own responsibility and with the high sense of social responsibility, forward-looking mind and the continuous effort in technological innovations, Dawnrays Pharma will keep offering high-quality and cost-saving medicines to the society, making ultimate contributions to the health of mankind.